Biogen Idec has applied to the U.S. Food & Drug Administration and the European Medicines Agency to extend the indication for Tysabri (natalizumab) to include first-line use in MS. The first-line indication would be for patients with relapsing MS who had tested negative for JC virus antibodies. At present, the indication for use of natalizumab is as a second-line treatment option for patients who fail prior therapy or have rapidly evolving MS. Su…

…There are now several studies indicating that vitamin D status affects selected clinical endpoints in MS, but evidence for treatment benefits has been mixed. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…